drugset
drugset / Trial / NCT03642834

Study of ICP-105 in Solid Tumors Patients

NCT03642834 ↗

Phase 1 Completed 21 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

Open-label, non-randomized, Phase I, dose-escalating, first-in-man study.

Timeline

Start
2018-09-21
Primary completion
2020-12-14
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ICP-105 Unknown 25 mg —
Subject ICP-105 Unknown 100 mg —

Indications

cancer